Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The investigators will evaluate weekly docetaxel plus 3-weekly cisplatin regimen as the first-line therapy for recurrent of metastatic nasophayngeal cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samsung Medical Center
• Treatments: Cisplatin; Docetaxel

Criteria

Inclusion Criteria:

• histologically confirmed nasopharyngeal cancer

• chemotherapy or radiotherapy naive (but, including patients completed 6 months before the enrollment)

• ECOG 0-1

• at least one measurable lesion

Exclusion Criteria:

• other cancer

• pregnat

• docetaxel hypersentitivity history

• severe heart or pulmonary disease